Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Talcott’s presentation focused on phase 2 clinical trial results of a therapeutic in development: EYP-1901, which aims to reduce treatment burden for wet AMD. This candidate is a bioerodible, ...

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing Tinlarebant's potential to treat geographic atrophy.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Suprachoroidal space (SCS) injection is an exciting method for the targeted delivery of therapies directly adjacent to affected chorioretinal tissues, potentially addressing several unmet needs in ...